Compare CPK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPK | TNGX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1995 | 2020 |
| Metric | CPK | TNGX |
|---|---|---|
| Price | $124.68 | $28.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $140.00 | $20.00 |
| AVG Volume (30 Days) | 117.7K | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | 13.50 | ★ 26.89 |
| EPS | ★ 5.97 | N/A |
| Revenue | ★ $930,000,000.00 | $62,384,000.00 |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $21.23 | ★ N/A |
| Revenue Growth | 18.14 | ★ 48.29 |
| 52 Week Low | $115.24 | $1.04 |
| 52 Week High | $140.59 | $27.16 |
| Indicator | CPK | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 78.56 |
| Support Level | $123.08 | $6.54 |
| Resistance Level | $126.05 | N/A |
| Average True Range (ATR) | 2.73 | 1.53 |
| MACD | -0.30 | 0.51 |
| Stochastic Oscillator | 2.06 | 96.95 |
Chesapeake Utilities Corp is a diversified energy delivery company that is engaged in natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions and other businesses. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland and Florida are subject to regulation by PSC. Eastern Shore, its natural gas transmission is subject to regulation by the FERC and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.